Home > News > Industry > Pharma News > Piramal Pharma invests...

Piramal Pharma invests over Rs 235 crore to expand Michigan facility

By - Ruchika Sharma
Published On 2020-12-08 08:30 GMT   |   Update On 2021-11-22 11:24 GMT

New Delhi: Piramal Pharma Solutions on Tuesday said it is investing around USD 32 million (over Rs 235 crore) to expand its facility in Michigan, US, with additional capacity and new capabilities for the development and manufacturing of active pharmaceutical ingredients (APIs). The company is investing the amount in the facility to keep up with expected demand based on current...

Login or Register to read the full article
Register Now

New Delhi: Piramal Pharma Solutions on Tuesday said it is investing around USD 32 million (over Rs 235 crore) to expand its facility in Michigan, US, with additional capacity and new capabilities for the development and manufacturing of active pharmaceutical ingredients (APIs).

The company is investing the amount in the facility to keep up with expected demand based on current forecasts, including potential new opportunities, Piramal Pharma Solutions said in a statement.

The expansion is planned to be ready for customers beginning summer 2022. It is expected that the expansion will add around twenty new hires to the site, bringing the total headcount to more than 180 employees and further benefiting the local economy, it added.
"Piramal Pharma Solutions' Riverview facility has a well-earned reputation as the preeminent leader in high potency APIs, and this expansion is designed to ensure that we retain that position," Piramal Pharma Solutions CEO Peter DeYoung said.
It enables the company to support its customers' immediate and long-term API needs, strengthens presence in North America, and enhances ability to serve patients around the world by delivering the active ingredients in a timely manner, he added.
Piramal Pharma Solutions is a contract development and manufacturing organisation, offering end-to-end development and manufacturing solutions across the drug life cycle.



Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Justify Rationality of FDC Meropenem plus Sodium Carbonate plus Avibactam: CDSCO Panel Tells Akum Pharmaceutical
Bayer, Evotec ink pact to advance precision cardiology
Janssen to adopt Johnson & Johnson brand in UK
Boehringer Ingelheim gets USFDA nod for high-concentration, citrate-free formulation of Cyltezo to treat multiple chronic inflammatory diseases
Labcorp gets USFDA nod for Companion Diagnostic for use with Pfizer hemophilia B Gene Therapy
Alkem Laboratories Gets CDSCO Panel Nod to Study Amoxicillin,Clavulanate Powder for reconstitution into suspension
Bharat Biotech Chief Dr Krishna M Ella named as new President of Indian Vaccine Manufacturers Association
Pneubevax 14 safe, immunogenic in 6-8 week old infants: Biological E